Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Interesting " "Joint Bookrunners") are acting as joint bookrunners in respect of the Placing. Beech Hill Securities, Inc. ("Beech Hill" and, together with the Joint Bookrunners, the "Banks") is acting as US placing agent."
https://www.beechhillsecurities.com/
Not quite what i was expecting anyway guess we start again - still believe value in the assets - hopefully when the dust settles company will make good progress with the science and will attract some serious biotech interest .
At first glance plans seem not to have changed .
Sorry for those of you disappointed , understandable re-action , anyway life goes on - maybe in a few months siituation will be better so happier times ahead .
Hi B2HS2L Link Might need to run it through translation :
http://affyxell.com/bbs/?so_table=news&mode=VIEW&num=38&category=&findType=&findWord=&sort1=&sort2=&page=1
Avacta JV recent update :
"Jeon Seung-ho, CEO of Daewoong Pharmaceutical, "Apicell, Nurturing into a Global Unicorn"
date 2024-01-25 14:14:55
FDA Pre-Clinical Meeting..."100% Achieved"
"2026 IPO Plans... Technology exports are also discussed."
"Apicell Therapeutics expects to enter Phase 1 clinical trials of AFX001 next year if it receives IND approval from the FDA. "
Jeon Seung-ho, CEO of Daewoong Pharmaceutical, was looking for a way to clarify the mechanism of action of mesenchymal stem cell therapy and discovered Abacta, a British biotech that has a similar antibody therapy technology 'Apimer Platform'. Since then, Daewoong Pharmaceutical's next-generation mesenchymal stem cell therapy ('DW-MSC') has verified the technology to inject the Apimer gene and established a joint venture 'Apicell Therapeutics' in 2020. Apicell Therapeutics, which is celebrating its fourth year of existence, is currently preparing for the U.S. Phase 1 clinical trial of its lead pipeline 'AFX001'./Photo=Lee Myung-geun qwe123@
Cell and gene therapy (CGT) is a new modality that global pharmaceutical companies are paying as much attention to as ADCs (antibody drug conjugates). According to the National Institute for Biotechnology Policy, the average annual growth rate of the global CGT market (2021~2027) is expected to reach 44.1%.
Daewoong Pharmaceutical, one of Korea's top five pharmaceutical companies, is also putting a lot of effort into the development of cell and gene therapies. The core base is 'Apicell Therapeutics'. It is a joint venture (joint venture) established by Jeon Seung-ho, CEO of Daewoong Pharmaceutical, in 2020 with British biotech Abacta while leading the open innovation project.
Apicell Therapeutics has the 'Apicell Platform' that combines the technologies of Daewoong Pharmaceutical and Abacta. It is a next-generation cell and gene therapy platform that injects genes into Daewoong Pharmaceutical's mesenchymal stem cell therapy ('DW-MSC'), which is capable of long-term transit culture (cell proliferation), to express 'Affimer', an antibody-like protein of Avacta.
CEO Jeon Seung-ho, who met at Daewoong Pharmaceutical's new building in Samseong-dong, Gangnam-gu, Seoul on the 24th, said, "Therapeutics made with the Apicell platform have the advantages of both stem cell therapy and antibody therapy," and "In preclinical trials, we confirmed the synergy effect (synergy) between Daewoong Pharmaceutical's and Avacta's platforms."
Recently, Apicell Therapeutics completed a pre-clinical trial plan (IND) meeting with the U.S. Food and Drug Administration (FDA) for the clinical entry of its lead pipeline 'AFX001' incorporating this technology. AFX001 is an autoimmune disease treatment that targets CD40L, which is involved in the mutual activation of T and B cells."
CA No conviction- Avacta was one of his best stock picks last month just a charlatan , at least the interviewee got it right good long term hold , science will prevail , future value is in the asset ,ignore the current SP etc .
Thanks Energyshares Yes listen to the experts not forgetting our key man Dr Tap in the USA & also Head Investigator at Leeds Hospital Prof Chris Twleves
https://twitter.com/avacta/status/1735703512695148582
-------
Dr William Tap, Chief, Sarcoma Medical Oncology at Memorial Sloan Kettering Cancer Center, NY also commented:
"These initial clinical data are encouraging and demonstrate that the novel drug delivery mechanism of AVA6000 has the potential to demonstrate single agent activity in patients with solid tumours that express high levels of FAP. The safety data when compared with standard doxorubicin are highly encouraging and demonstrate the power of the pre|CISION? platform to avoid normal tissue effects while concentrating the toxin in the tumor microenvironment."
Good Morning
David Wilson Avacta Chief Commercial Officer | Driving Global IVD Business Growth
liked this : Perhaps opportunity for Avacta Launch Diagnostics .
https://www.bivda.org.uk/Portals/0/documents/External_Affairs/BIVDA%20AMR%20Consensus%20Statement%20Final.pdf?ver=IcdF3HfhVEEjnR-rvH5hiw%3d%3d
https://www.launchdiagnostics.com/product/liofilchem-mic-test-strip-mts/
-----------------------------------
Linkedin
"British In Vitro Diagnostics Association (BIVDA)British In Vitro Diagnostics Association (BIVDA)
5,412 followers5,412 followers
19h • Edited • 19h • Edited •
Follow
📢 Coalition calls for testing to tackle threat of Antimicrobial Resistance
A new coalition of industry and health charities, led by former Health Minister, raise the alarm over missed opportunities to tackle Antimicrobial Resistance in the UK.
Action urgently needed to adopt point of care diagnostics and end years of delay in implementing key recommendations for antimicrobial stewardship.
A cross-sector coalition of health and diagnostics organisations are calling for urgent action to combat the imminent threat of antimicrobial resistance (AMR).
Led by the British In Vitro Diagnostics Association (BIVDA) and the former Health Minister, Maggie Throup MP, who was responsible for the roll out of the COVID-19 vaccine, the coalition is highlighting missed opportunities to use proven diagnostic technology that can help to reduce prescribing of antibiotics when they are not needed.
Supporting the coalition, former Minister for Vaccines and Public Health, Maggie Throup MP said “I am deeply concerned about the slow progress that has been made to support the use of point of care tests as part of the UK’s antimicrobial stewardship efforts. AMR is a tremendous threat, and it is critical that we don’t miss opportunities to slow the progress of resistance. That is why we are calling on the government to prioritise the effective adoption of point of care testing in community and primary care settings.
The pandemic underlined that the government and health system can move quickly to roll-out diagnostics and respond to major health threats – we must act now, with the same urgency, to tackle the problem of AMR.”
Deaths in the UK related to hashtag#AMR are estimated to stand at 12,000 per year, the equivalent of deaths from breast cancer each year, and more deaths than from suicide (approx. 6,500). Ten million people each year are predicted to die globally from AMR by 2050 unless urgent measures are taken.
Coming together to set out a call to action for government and the NHS, the cross-sector coalition has expressed concern over the extended delays to implementing key recommendations on using point-of-care tests to tackle AMR. "
LD liked this manufacturer product
https://www.launchdiagnostics.com/product/bosphore-streptococcus-pneumoniae-detection-kit-v1/
-------------------
"Anatolia GeneworksAnatolia Geneworks
4,721 followers4,721 followers
9h • 9h •
Follow
Early Strep A treatment is important!
Streptococcus pyogenes, the bacterium that causes Strep A, creates flu-like symptoms, nausea, vomiting and, most importantly, a sore throat. The disease can be fatal in children under 15 and people over 65. Rapid treatment is possible with early diagnosis. Bosphore Streptococcus pyogenes (Group A) Detection Kit provides fast and reliable results and helps initiate rapid intervention."
November 2023 Nice little article on affimers if not seen before - promising asset waiting in the wings
https://benchmarkantibodies.com/index.php/2023/11/02/affimers-the-rising-stars-in-molecular-recognition/
Have devastating side effects - need for novel solutions - Huge global market for Avacta US $ 331 billion by end 2032 .
Very good reason for shareholders to hang around , no reason Avacta will not eventually , get a slice of that revenue cake .
------------------
The pre|CISION™ tumour microenvironment activated chemotherapy platform releases active drug only within the tumour microenvironment – limiting systemic exposure and enhancing the safety and therapeutic potential of treatments for oncology indications. The pre|CISION™ tumour microenvironment activated chemotherapy platform releases active drug only within the tumour microenvironment – limiting systemic exposure and enhancing the safety and therapeutic potential of treatments for oncology indications. The pre|CISION™ tumour microenvironment activated chemotherapy platform releases active drug only within the tumour microenvironment – limiting systemic exposure and enhancing the safety and therapeutic potential of treatments for oncology indications.
---------------------------------------
https://www.persistencemarketresearch.com/market-research/chemotherapy-drugs-market.asp#:~:text=Worldwide%20revenue%20from%20the%20chemotherapy%20drugs%20market%20is,the%20last%209%20years%20from%202012%20to%202021.
Great to see ONDO making progress with Water companies ,
https://twitter.com/foster_ideas/status/1762010879648833824
Craig Foster
@foster_ideas
·
1h
8% of UK toilets leak - wasting 400 ml/day - enough water to meet the needs of Birmingham, Manchester, Sheffield and Leeds.
LeakBot can find and fix them. Significant step today with South West Water deploying 6,000 LeakBots in a rapid intervention re to reduce leaks #ONDO
Quote
Ondo InsurTech Plc
@OndoPlc
·
1h
*RNS* @SouthWestWater deploy LeakBot to prevent water leaks. South West Water, part of Pennon Group PLC, provides water and wastewater services to 1.8 million customers across the South West. #ONDO #MadeInBritain #GreenEconomy
https://londonstockexchange.com/news-article/ONDO/new-agreement-with-south-west-water/16347683
Good Morning added a few more , every confidence Avacta will deliver , expect positive news flow throughout 2024 so the journey starts again , first step see my current deficit -33.75% decrease then onwards /upwards we go ..
Have a fun day in the AVCT madhouse .
Avacta have a licence with PB/Lilly : Might be of interest .
"Leila SafaviLeila Safavi
• 3rd+• 3rd+
Innovative Entrepreneur and CEO | Nuclear Technology Expert | Revolutionizing Healthcare with Radioisotopes | Forbes NEXT 1000 Entrepreneur | Oncidium Foundation AmbassadorInnovative Entrepreneur and CEO | Nuclear Technology Expert | Revolutionizing Healthcare with Radioisotopes | Forbes NEXT 1000 Entrepreneur | Oncidium Foundation Ambassador
1d • 1d •
Follow
☢️ Shining a Light on Progress: Radioisotope Clinical Trials Update! ☢️
The field of radiopharmaceuticals is booming, with innovative therapies utilizing radioisotopes like Lu-177, Ac-225, and Pb-212 holding immense potential for treating various diseases. But where do these promising treatments stand in terms of clinical trials?
I'm sharing this image to visualize the current landscape of radioisotope clinical trials. Each isotope offers unique properties and therapeutic advantages, and the image provides a snapshot of their progress.
It's crucial to remember that this is just a glimpse into the dynamic world of radioisotope clinical trials. Here are some additional points to consider:
💫Rapidly evolving landscape: New radioisotopes and targeted agents emerge constantly, pushing the boundaries of clinical research.
💫Collaborative efforts: Partnerships between researchers, clinicians, and pharmaceutical companies are crucial for accelerating development and overcoming challenges.
💫 Focus on unmet needs: Radiopharmaceuticals offer hope for patients with limited treatment options, driving continued investment and research efforts.
🚀 The future is bright: The progress highlighted, along with the ongoing research and development, paints a promising picture for the future of radioisotope therapy. These targeted treatments have the potential to revolutionize healthcare, offering personalized and effective solutions for a wider range of diseases.
Join the conversation!
💡What excites you most about the potential of radioisotope therapies?
💡Are there specific diseases you hope these treatments will address?
💡What role can we play in supporting the advancement of this field?
Share your thoughts and questions in the comments below! Let's continue to shine a light on the progress and potential of radioisotope clinical trials.
Activate to view larger image,
Image preview
https://www.linkedin.com/posts/leilasafavi_shining-a-light-on-progress-radioisotope-activity-7165832523615334402-hfhT/
Why is Wyn not buying --- RSI signals flashing SP between 14 Day RSI at 30% 88.794 - 14 Day RSI at 20% 77.584 ?
Surely loading up ?
https://www.barchart.com/stocks/quotes/AVCT.LN/cheat-sheet
Or of course you could just hold and/or buy a few more , easy to view the past & repetitively ask why why why ?Will not change anything .
Personally i have high expectations that the future is indeed very bright for Avacta shareholders .
Good that Avacta have JV partners making progress using affimer techonology .:
"Company Introduction
Apicell Therapeutics Co., Ltd. is a company specializing in the development of next-generation cell and gene therapy products jointly funded by Daewoong Pharmaceutical and Avacta Life Science in the UK.
We are developing next-generation cell and gene therapy products (AFX platform technology) optimized for immune modulation by combining the Affimer platform technology to strengthen immune modulation based on the next-generation mesenchymal stem cell platform technology that overcomes the limitations of adult tissue-derived mesenchymal stem cells."